Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation

International Journal of Pharmaceutics

Volumn 481, Issue 1-2, 2015, Pages 154-161

  Danhier, Fabienne ^a   Messaoudi, Khaled ^b   Lemaire, Laurent ^b   Benoit, Jean Pierre ^b,c   Lagarce, Frédéric ^b,c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Laboratoire d'Acoustique Environnementale   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

EGFR; Galectin 1; Glioblastoma; Lipid nanocapsules; siRNA; Temozolomide

Indexed keywords

CHITOSAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GALECTIN 1; NANOCAPSULE; SMALL INTERFERING RNA; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENE SILENCING; GENETICS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHITOSAN; DACARBAZINE; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GALECTIN 1; GENE SILENCING; GLIOBLASTOMA; HUMANS; LIPIDS; MICE, NUDE; NANOCAPSULES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; TUMOR BURDEN;

EID: 84922801507     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.01.051     Document Type: Article

References (40)

1. L. Aagaard, and J.J. Rossi RNAi therapeutics: principles prospects and challenges Adv. Drug Deliv. Rev. 59 2007 75 86
2. N.J. Abbott, A.A. Patabendige, D.E. Dolman, S.R. Yusof, and D.J. Begley Structure and function of the blood-brain barrier Neurobiol. Dis. 37 2010 13 25
3. R. Ahmed, M.J. Oborski, M. Hwang, F.S. Lieberman, and J.M. Mountz Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Cancer Manage. Res. 6 2014 149 170
4. E. Allard, C. Passirani, and J.P. Benoit Convection-enhanced delivery of nanocarriers for the treatment of brain tumors Biomaterials 30 2009 2302 2318
5. A. Bernardi, E. Braganhol, E. Jager, F. Figueiro, M.I. Edelweiss, and A.R. Pohlmann Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model Cancer Lett. 281 2009 53 63
6. I. Camby, N. Belot, F. Lefranc, N. Sadeghi, Y. de Launoit, and H. Kaltner Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases J. Neuropathol. Exp. Neurol. 61 2002 585 596
7. I. Camby, C. Decaestecker, F. Lefranc, H. Kaltner, H.J. Gabius, and R. Kiss Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern Biochem. Biophys. Res. Commun. 335 2005 27 35
8. D. Castanotto, K. Sakurai, R. Lingeman, H. Li, L. Shively, and L. Aagaard Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC Nucleic Acids Res. 35 2007 5154 5164
9. A. Clavreul, C. Guette, R. Faguer, C. Tetaud, A. Boissard, and L. Lemaire Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties J. Pathol. 233 2014 74 88
10. S. Doblas, T. He, D. Saunders, J. Pearson, J. Hoyle, N. Smith, M. Lerner, and R.A. Towner Glioma morphology and tumor-induced vascular alterations revealed in seven rodent glioma models by in vivo magnetic resonance imaging and angiography J. Magn. Reson. Imaging 32 2010 267 275
11. A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. Mello Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 1998 806 811
12. H.S. Friedman, T. Kerby, and H. Calvert Temozolomide and treatment of malignant glioma Clin. Cancer Res. 6 2000 2585 2597
13. K.J. Hatanpaa, S. Burma, D. Zhao, and A.A. Habib Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance Neoplasia 12 2010 675 684
14. C.H. Heldin, K. Rubin, K. Pietras, and A. Ostman High interstitial fluid pressure - an obstacle in cancer therapy Nat. Rev. Cancer 4 2004 806 813
15. B. Heurtault, P. Saulnier, B. Pech, J.E. Proust, and J.P. Benoit A novel phase inversion-based process for the preparation of lipid nanocarriers Pharm. Res. 19 2002 875 880
16. J. Hureaux, F. Lagarce, F. Gagnadoux, L. Vecellio, A. Clavreul, and E. Roger Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel Eur. J. Pharm. Biopharm. 73 2009 239 246
17. T. Kato, A. Natsume, H. Toda, H. Iwamizu, T. Sugita, and R. Hachisu Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells Gene Ther. 17 2010 1363 1371
18. D.H. Kim, and J.J. Rossi Strategies for silencing human disease using RNA interference Nat. Rev. Genet. 8 2007 173 184
19. Q.T. Le, G. Shi, H. Cao, D.W. Nelson, Y. Wang, and E.Y. Chen Galectin-1: a link between tumor hypoxia and tumor immune privilege J. Clin. Oncol. 23 2005 8932 8941
20. F. Lefranc, N. Sadeghi, I. Camby, T. Metens, O. Dewitte, and R. Kiss Present and potential future issues in glioblastoma treatment Expert Rev. Anticancer Ther. 6 2006 719 732
21. M. Le Mercier, F. Lefranc, T. Mijatovic, O. Debeir, B. Haibe-Kains, and G. Bontempi Evidence of galectin-1 involvement in glioma chemoresistance Toxicol. Appl. Pharmacol. 229 2008 172 183
22. J. Malmo, H. Sorgard, K.M. Varum, and S.P. Strand siRNA delivery with chitosan nanoparticles: molecular properties favoring efficient gene silencing J. Control. Release 158 2012 261 268
23. M.T. McManus, and P.A. Sharp Gene silencing in mammals by small interfering RNAs Nat. Rev. Genet. 3 2002 737 747
24. D.K. Moscatello, M. Holgado-Madruga, D.R. Emlet, R.B. Montgomery, and A.J. Wong Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor J. Biol. Chem. 273 1998 200 206
25. H. Ngo, C. Tschudi, K. Gull, and E. Ullu Double-stranded RNA induces mRNA degradation in Trypanosoma brucei Proc. Natl. Acad. Sci. 95 1998 14687 14692
26. K. Messaoudi, P. Saulnier, K. Boesen, J.P. Benoit, and F. Lagarce Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide Int. J. Nanomed. 9 2014 1479 1490
27. K. Messaoudi, A. Clavreul, F. Danhier, P. Saulnier, J.P. Benoit, and F. Lagarce Combined silencing expression of MGMT with EGFR or Galectin-1 enhances the sensitivity of glioblastoma to temozolomide Eur. J. Nanomed. 2014 Submitted
28. D. Reischl, and A. Zimmer Drug delivery of siRNA therapeutics: potentials and limits of nanosystems Nanomedicine 5 2009 8 20
29. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, and R.C. Janzer Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 10 2009 459 466
30. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, and M.J. Taphoorn Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 2005 987 996
31. S. Techaarpornkul, S. Wongkupasert, P. Opanasopit, A. Apirakaramwong, J. Nunthanid, and U. Ruktanonchai Chitosan-mediated siRNA delivery in vitro: effect of polymer molecular weight concentration and salt forms AAPS PharmSciTech 11 2010 64 72
32. O. Thomas, and F. Lagarce Lipid nanocapsules: a nanocarrier suitable for scale-up process J. Drug Deliv. Sci. Technol. 23 2013 555 559
33. T. Tsujiuchi, A. Natsume, K. Motomura, G. Kondo, M. Ranjit, and R. Hachisu Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains Am. J. Trans. Res. 6 2014 169 178
34. C. Vanpouille-Box, F. Lacoeuille, C. Belloche, N. Lepareur, L. Lemaire, and J.J. LeJeune Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules Biomaterials 32 2011 6781 6790
35. M. Verreault, S.A. Weppler, A. Stegeman, C. Warburton, D. Strutt, and D. Masin Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model PLoS One 8 2013 e59597
36. A.A. Volkov, N.S. Kruglova, M.I. Meschaninova, A.G. Venyaminova, M.A. Zenkova, and V.V. Vlassov Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect Oligonucleotides 19 2009 191 202
37. N. Wauthoz, P. Deleuze, J. Hecq, I. Roland, S. Saussez, and I. Adanja In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy Eur. J. Pharma. Sci. 39 2010 402 411
38. H.Y. Xue, S. Liu, and H.L. Wong Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine Nanomedicine (Lond.) 9 2014 295 312
39. J. Zhang, M.F. Stevens, and T.D. Bradshaw Temozolomide: mechanisms of action repair and resistance Curr. Mol. Pharmacol. 5 2012 102 114
40. Z.X. Zhao, S.Y. Gao, J.C. Wang, C.J. Chen, E.Y. Zhao, W.J. Hou, Q. Feng, L.Y. Gao, X.Y. Liu, L.R. Zhang, and Q. Zhang Self-assembly nanomicelles based on cationic mPEG-PLA-b-polyarginine(R15) triblock copolymer for siRNA delivery Biomaterials 33 2012 6793 6807